San Diego-centered Viking Therapeutics marked alone as a serious competitor in the weight loss drug market place in February immediately after revealing promising knowledge from a mid-phase demo of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when given to be a weekly injection and in March the compa